- Home
- VVR vs LAB Comparison
VVR vs LAB Comparison
Compare VVR & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVR
- LAB
- Stock Information
- Founded
- VVR 1998
- LAB 1999
- Country
- VVR United States
- LAB United States
- Employees
- VVR N/A
- LAB N/A
- Industry
- VVR Trusts Except Educational Religious and Charitable
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- VVR Finance
- LAB Industrials
- Exchange
- VVR Nasdaq
- LAB Nasdaq
- Market Cap
- VVR 574.6M
- LAB 505.7M
- IPO Year
- VVR N/A
- LAB 2011
- Fundamental
- Price
- VVR $3.77
- LAB $1.30
- Analyst Decision
- VVR
- LAB Buy
- Analyst Count
- VVR 0
- LAB 2
- Target Price
- VVR N/A
- LAB $2.50
- AVG Volume (30 Days)
- VVR 692.2K
- LAB 1.6M
- Earning Date
- VVR 01-01-0001
- LAB 08-11-2025
- Dividend Yield
- VVR 11.38%
- LAB N/A
- EPS Growth
- VVR N/A
- LAB N/A
- EPS
- VVR N/A
- LAB N/A
- Revenue
- VVR N/A
- LAB $169,687,000.00
- Revenue This Year
- VVR N/A
- LAB N/A
- Revenue Next Year
- VVR N/A
- LAB $12.18
- P/E Ratio
- VVR N/A
- LAB N/A
- Revenue Growth
- VVR N/A
- LAB 33.86
- 52 Week Low
- VVR $3.55
- LAB $0.92
- 52 Week High
- VVR $4.38
- LAB $2.32
- Technical
- Relative Strength Index (RSI)
- VVR 53.50
- LAB 49.88
- Support Level
- VVR $3.69
- LAB $1.36
- Resistance Level
- VVR $3.79
- LAB $1.45
- Average True Range (ATR)
- VVR 0.04
- LAB 0.08
- MACD
- VVR -0.00
- LAB -0.01
- Stochastic Oscillator
- VVR 64.17
- LAB 28.57
About VVR Invesco Senior Income Trust (DE)
Invesco Senior Income Trust is a diversified, closed-end management investment company. The investment objective of the company is to provide a high level of current income, consistent with the preservation of capital. The company invests in a portfolio of interests in floating or variable senior loans to corporations, partnerships, and other entities which operate in a variety of industries and geographic regions.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.